-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NVgTBLRU1o2CHqvxLq6UAIbLKNY62we/G8dOcNanQslVtOWqHu1KowaT59jNSf9x fs3yhbjg4/8WuWYZKIAmjQ== 0000909567-04-001530.txt : 20041103 0000909567-04-001530.hdr.sgml : 20041103 20041103092138 ACCESSION NUMBER: 0000909567-04-001530 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20041103 DATE AS OF CHANGE: 20041103 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KYTO BIOPHARMA INC CENTRAL INDEX KEY: 0001164888 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 651086538 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-80125 FILM NUMBER: 041114904 BUSINESS ADDRESS: STREET 1: 41A AVENUE ROAD AT YORK SQUARE CITY: TORONTO ONTARIO STATE: A1 ZIP: 00000 BUSINESS PHONE: 416-955-0159 FORMER COMPANY: FORMER CONFORMED NAME: B TWELVE INC DATE OF NAME CHANGE: 20020111 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BENARROCH GEORGES CENTRAL INDEX KEY: 0001051339 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 78 HAZERTON AVENUE STREET 2: TORONTO ONTARIO CITY: CANADA M5R 2E2 STATE: A6 ZIP: 00000 BUSINESS PHONE: 4169550159 MAIL ADDRESS: STREET 1: 78 HAZELTON AVENUE STREET 2: TORONTO ONTARIO CITY: CANADA M5R 2E2 STATE: A6 ZIP: 00000 SC 13D 1 t14543bsc13d.txt SC 13D Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a valid OMB control number. ------------------------ OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Act of 1934 (Amendment No. *) KYTO BIOPHARMA INC. (Name of Issuer) COMMON STOCK $.0001 PAR VALUE (Title of Class of Securities) 501572101 (CUSIP Number) MICHAEL S. SINGER 3801 PGA BLVD # 802 PALM BEACH GARDENS FL 33407 COPY TO: JEAN-LUC BERGER, 41A AVENUE ROAD TORONTO ON M5R 2G3 (416-955-0162) (Name, Address and Telephone Number of Person Authorized to Receive Notices & Communications) AUGUST 2, 2004 --------------- (Date of Event which requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box / /. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. (Page 1 of 4 Pages)
CUSIP No. 501572101 Page 2 of 4 1) Names of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons GEORGES BENARROCH S.S./IRS NO. NOT APPLICABLE ------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (See Instructions) A) B) 3) SEC Use Only 4) Source of Funds OO (SEE ITEM 3) ---------------------------------------------------------------------------------- 5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(c) 6) Citizenship or Place of Organization CANADIAN ---------------------------------------------------------------------------------- Number of (7) Sole Voting Power 30,025 ----------------------------------- Shares Bene- ficially (8) Shared Voting Power --------------------------------- Owned by Each Report- (9) Sole Dispositive Power 30,025 ------------------------------ ing Person With (10) Shared Dispositive Power ----------------------------- 11) Aggregate Amount Beneficially Owned by Each Reporting Person 30,025 ---------------------------------------------------------------------------------- 12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13) Percent of Class Represented by Amount in Row (11) 0.046% ---------------------------------------------------------------------------------- 14) Type of Reporting Person (See Instruction) IN ----------------------------------------------------------------------------------
CUSIP No. 50157201 Page 3 of 4 ITEM 1. SECURITY AND BACKGROUND Common Stock, $.0001 par value per share Kyto BioPharma Inc. 3801 PGA Blvd. Suite 802 Palm Beach Gardens FL 33407 ITEM 2. IDENTITY AND BACKGROUND This statement is a single filing of Georges Benarroch, a Canadian citizen, 68 Rue Spontini, Paris, France 75016. Mr. Benarroch is a Director of Kyto BioPharma Inc. During the last five years, Mr. Benarroch has not been convicted in a criminal proceeding, nor has he been a party to a civil proceeding as a result of which he was subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION The shares of Common Stock beneficially owned by Georges Benarroch were granted by the Issuer to the reporting person as director's fees. ITEM 4. PURPOSE OF THE TRANSACTION The reporting person filing this statement does not have any present plans or proposals which relate to or would result in: a) The acquisition by any person of additional securities of the issuer, or the disposition of such securities; b) An extraordinary corporation transaction, such as a merger, reorganization or liquidation involving the issuer or any of its subsidiaries; c) A sale or transfer of a material amount of the assets of the issuer or any of its subsidiaries; d) Any change in the board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; e) Any material change in the present capitalization or dividend policy of the issuer; f) Any other material change in the issuer's business or corporate structure; g) Changes in the issuer's charter, bylaws or instruments corresponding thereto, or other actions which may impede the acquisition of control of the issuer by any person; CUSIP No. 501572101 Page 4 of 4 h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or j) Any action similar to any of those enumerated above. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Mr. Benarroch, by virtue of his position and security holding, is the beneficial owner of 30,025 shares of Common Stock, or 0.046%. No transactions in shares of Common Stock of the issuer were effected by the reporting person during the last 60 days. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER There are no contracts, arrangements, understandings or relationships (legal or otherwise) between the person named in Item 2 and any person with respect to any securities of the issuer. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. /s/ Georges Benarroch Dated: September 8, 2004 ___________________________________ GEORGES BENARROCH -----END PRIVACY-ENHANCED MESSAGE-----